Outlook Therapeutics downgraded by H.C. Wainwright with a new price target

8/31/23 7:18:56 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral and set a new price target of $1.00 from $5.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OTLK

Date	Price Target	Rating	Analyst
12/2/2024		Buy → Neutral	Chardan Capital Markets
3/27/2024	$50.00	Neutral → Buy	BTIG Research
2/15/2024	$3.00	Neutral → Buy	Chardan Capital Markets
1/25/2024		Neutral → Buy	Guggenheim
12/27/2023	$5.00	Equal Weight → Overweight	CapitalOne
8/31/2023	$5.00 → $1.00	Buy → Neutral	H.C. Wainwright
8/31/2023		Buy → Neutral	Chardan Capital Markets
8/30/2023		Overweight → Equal Weight	CapitalOne